CLAIM AMENDMENTS

Please cancel claims 2, 3, 5, 16, and 17.

1. (Original) A use of a plasminogen activator for manufacturing a medicament for increasing an effect caused by IL-2 inhibitor.

2. (Canceled)

3. (Canceled)

4. (Original) The use of the claim 1, in which the effect caused by IL-2 inhibitor is a neuroprotective activity.

5. (Canceled)

6. (Original) A use of a plasminogen activator and IL-2 inhibitor for manufacturing a medicament for simultaneous, separate or sequential use for neuroprotective activity.

7. (Original) A method for increasing an effect caused by IL-2 inhibitor, by administering a effective amount of a plasminogen activator to a human being or an animal.

8. (Currently Amended) A method for preventing or treating ~~acute or chronic~~ cerebral ~~neurodegenerative diseases~~ ischemic disease and/or brain damage caused by ischemia~~, by~~ comprising administering ~~a~~ an effective amount of ~~a plasminogen activator~~ t-PA and an effective amount of ~~IL-2 inhibitor~~ tacrolimus or its hydrate, simultaneously~~, separately~~ or ~~in sequential use~~ sequentially, to a human being or an animal.

9. (Original) A composition comprising a plasminogen activator, for increasing an effect caused by IL-2 inhibitor.

10. (Original) A composition comprising a plasminogen activator and IL-2 inhibitor as a combined preparation for simultaneous, separate or sequential use for neuroprotective activity.

11. (Original) An article of manufacture, comprising packaging material and a plasminogen activator contained within said packaging material, wherein said plasminogen activator is therapeutically effective for increasing an effect caused by IL-2 inhibitor, and wherein said packaging material comprises a label or a written material which indicates that said plasminogen activator can be used for increasing an effect caused by IL-2 inhibitor.

12. (Original) A use of IL-2 inhibitor for manufacturing a medicament for increasing or decreasing an effect caused by plasminogen activator, in which the effect caused by plasminogen activator is a neuroprotective activity or a brain damage appeared in case that plasminogen activator is administered after its proper therapeutic time.

13. (Original) A method for increasing or decreasing an effect caused by plasminogen activator, by administering a effective amount of IL-2 inhibitor, in which the effect caused by plasminogen activator is a neuroprotective activity or a brain damage appeared in case that plasminogen activator is administered after its proper therapeutic time.

14. (Original) A composition comprising IL-2 inhibitor, for increasing or decreasing an effect caused by plasminogen activator.

15. (Original) An article of manufacture, comprising packaging material and IL-2 inhibitor contained within said packaging material, wherein said IL-2 inhibitor is therapeutically effective for increasing or decreasing an effect caused by plasminogen activator, and wherein said packaging material comprises a label or a written material which indicates that said IL-2 inhibitor can be used for increasing or decreasing an effect caused by plasminogen activator.

16. (Canceled)

17. (Canceled)

18. (Currently Amended) The method of ~~the~~ claim 8, ~~in which~~ wherein the ~~acute or chronic~~ cerebral ~~neurodegenerative disease is cerebral~~ ischemic disease and/or brain damage caused by ischemia is cerebral infarction.

19. (Currently Amended)) The method of ~~the~~ claim 8, ~~in which~~ wherein the ~~acute or chronic~~ cerebral ~~neurodegenerative disease~~ ischemic disease and/or brain damage caused by ischemia

is selected from the group consisting of cerebral infarction, head injury, subarachnoid hemorrhage ~~in brain~~, intracerebral hemorrhage, cerebral thrombosis, cerebral embolism, cardiac arrest, stroke, and transient ischemic attacks (TIA) ~~, hypertensive encephalopathy, Alzheimer's disease, Huntington's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS)~~.

20. (Currently Amended) The method of ~~the~~ claim 8, ~~in which~~ wherein the ~~acute or chronic~~ cerebral ~~neurodegenerative disease~~ ischemic disease and/or brain damage caused by ischemia is acute stroke.

Please add the following new claims.

21. (New) The method of claim 8, comprising administering the effective amount of t-PA and the effective amount of tacrolimus or its hydrate 2 hours after the occurrence of the cerebral ischemic disease and/or brain damage caused by ischemia.

22. (New) The method of claim 8, comprising administering the effective amount of t-PA and the effective amount of tacrolimus or its hydrate 3 hours after the occurrence of the cerebral ischemic disease and/or brain damage caused by ischemia.

23. (New) The method of claim 21, comprising administering the effective amounts of t-PA and tacrolimus or its hydrate simultaneously.

24. (New) The method of claim 22, comprising administering the effective amounts of t-PA and tacrolimus or its hydrate simultaneously.

25. (New) The method of claim 21, comprising administering the effective amounts of t-PA and tacrolimus or its hydrate sequentially.

26. (New) The method of claim 22, comprising administering the effective amounts of t-PA and tacrolimus or its hydrate sequentially.